Release Date: 2024-05-28

Adjuvant Intravesical Immunotherapy

Bekir Demirtas (Author), Mehmet Caglar Cakici (Author)

Release Date: 2024-05-28

Adjuvant intravesical immunotherapy is recognized as an effective treatment option for various urological cancer types. It plays a significant role in reducing the risk of recurrence, particularly in high-risk non-muscle-invasive bladder cancer cases. This treatment method is commonly utilized to diminish tumor residues following transurethral resection and prevent disease progression. Among the most frequently employed [...]

Media Type

  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inCurrent Management of Non-Muscle Invasive Bladder Cancer
First Page121
Last Page131
DOIhttps://doi.org/10.69860/nobel.9786053359197.10
ISBN978-605-335-919-7 (PDF)
LanguageENG
Page Count11
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

Adjuvant intravesical immunotherapy is recognized as an effective treatment option for various urological cancer types. It plays a significant role in reducing the risk of recurrence, particularly in high-risk non-muscle-invasive bladder cancer cases. This treatment method is commonly utilized to diminish tumor residues following transurethral resection and prevent disease progression. Among the most frequently employed agents are BCG (Bacillus Calmette-Guérin) and interferon. Adjuvant intravesical immunotherapy is typically administered alongside or following other treatment modalities to minimize local and systemic side effects. Due to its low invasiveness and relatively high efficacy, this treatment holds a crucial place in the management of non-muscle-invasive bladder cancer.

Bekir Demirtas (Author)
Istanbul Medeniyet University
https://orcid.org/0000-0002-0410-8866
3I graduated from Kocaeli University Faculty of Medicine in 2018 and currently serve as a urology resident. Throughout my career, I have contributed to both national and international publications in the field. Additionally, I have had the privilege of collaborating with esteemed professionals abroad and participating in various conferences. My experiences have enriched my understanding of urology and equipped me with valuable insights into global healthcare practices. I am passionate about advancing the field through research and clinical practice, striving to make meaningful contributions to patient care and scientific discourse.

Mehmet Caglar Cakici (Author)
Associate Professor, Istanbul Medeniyet University
https://orcid.org/0000-0002-0176-5887
3Mehmet Çağlar Çakıcı completed his undergraduate education at Gazi University Faculty of Medicine in 2012. He finished his urology specialization training in 2018 at Ankara Diskapi Yildirim Beyazit Training and Research Hospital. In the same year, he started working as a urology specialist at Istanbul Medeniyet University Goztepe Training and Research Hospital, and he currently continues his work at the same hospital as an associate professor. He has authored over seventy articles and participated as an investigator in ten clinical studies.

  • 1. Huang Z, Liu H, Wang Y, Zhang C, Xu T. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis. Curr Med Res Opin 2017;33(8):1379–87.

  • 2. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol 2016;196(4):1021–9.

  • 3. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol 2019;76(5):639–57.

  • 4. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008;179(1):53–6.

  • 5. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116(2):180–2.

  • 6. Brossman SA. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1982;128(1):27–30.

  • 7. Mukherjee N, Svatek R. Cancer Immune therapy: Prognostic significance and implications for therapy of PD-1 in BCG-relapsing bladder cancer. Ann Surg Oncol 2018;25(9):2498.

  • 8. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, et al. PD-L1 (B7- H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 2007;109(8):1499– 505.

  • 9. Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol 2014;11(3):153– 62.

  • 10. Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003;170(3):964–9.

  • 11. Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 1987;137(1):155–8.

  • 12. Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88(3):209–16.

  • 13. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169(1):90–5.

  • 14. Sylvester RJ, Van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168(5):1964–70.

  • 15. Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57(5):766–73.

  • 16. Unda-Urzaiz M, Cozar-Olmos JM, Miñana-Lopez B, Camarero-Jimenez J, Brugarolas-Rossello X, Zubiaur-Libano C, et al. Safety and efficacy of various strains of bacille Calmette-Guérin in the treatment of bladder tumors in standard clinical practice. Actas Urol Esp 2018;42(4):238–48.

  • 17. Palou J, Laguna P, Millán-Rodríguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodríguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol. 2001 May;165(5):1488-91.

  • 18. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124-9.

  • 19. Oddens J, Brausi M, Sylvester R, Bono A, Van De Beek C, Van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63(3):462–72.

  • 20. Brausi M, Oddens J, Sylvester R, Bono A, Van De Beek C, Van Andel G, et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing onethird dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014;65(1):69–76.

  • 21. Saint F, Le Frere Belda MA, Quintela R, Hoznek A, Patard JJ, Bellot J, et al. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG). Eur Urol 2004;45(4):475–82.

  • 22. Danielsson G, Malmström PU, Jahnson S, Wijkström H, Nyberg T, Thulin H. Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer - a follow-up five years after the start of treatment. Scand J Urol 2018;52(5– 6):377–84.

  • 23. Larsen ES, Nordholm AC, Lillebaek T, Holden IK, Johansen IS. The epidemiology of bacille Calmette-Guérin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int 2019;124(6):910–6.

  • 24. Lamm DL. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000;31 Suppl 3(SUPPL. 3). Available from: https://pubmed.ncbi.nlm.nih.gov/11010830/

  • 25. Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK. BCG intravesical instillations: recommendations for side-effects management. Eur Urol 2000;37 Suppl 1(SUPPL. 1):33–6. Available from: https://pubmed.ncbi.nlm.nih.gov/10575271/

  • 26. Lamm DL. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am. 1992;19(3):565-72. PMID: 1636240.

  • 27. Wittes R, Klotz L, Kosecka U. Severe bacillus Calmette-Guerin cystitis responds to systemic steroids when antituberculous drugs and local steroids fail. J Urol. 1999;161(5):1568-9. PMID: 10210404.

  • 28. Larsen ES, Joensen UN, Poulsen AM, Goletti D, Johansen IS. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. APMIS 2020 2024;128(2):92–103. Available from: https://pubmed.ncbi.nlm.nih.gov/31755155/

  • 29. Jue JS, Alameddine M, González J, Ciancio G. Risk factors, management, and survival of bladder cancer after kidney transplantation. Actas Urol Esp 2021;45(6):427–38.

  • 30. Roumeguère T, Broeders N, Jayaswal A, Rorive S, Quackels T, Pozdzik A, et al. Bacillus Calmette-Guerin therapy in non-muscle-invasive bladder carcinoma after renal transplantation for end-stage aristolochic acid nephropathy. Transpl Int [Internet]. 2015;28(2):199–205.

  • 31. Lamm DL, Van der Meijden APM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147(3):596–600.

  • 32. Belldegrun AS, Franklin JR, O’Donnell MA, Gomella LG, Klein E, Neri R, et al. Superficial bladder cancer: the role of interferon-alpha. J Urol 1998;159(6):1793– 801.

  • 33. Lamm, D. L. KLH immunotherapy of papillary and in situ transitional cell carcinoma of the bladder: a multicenter phase I-II clinical trial. J Urol 1996;155:662A-.

  • 34. Jurincic CD, Engelmann U, Gasch J, Klippel KF. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J Urol 1988;139(4):723–6. Available from: https://pubmed.ncbi.nlm.nih.gov/3127600/

  • 35. Sarosdy MF, Manyak MJ, Sagalowsky AI, Belldegrun A, Benson MC, Bihrle W, et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. Urology 1998;51(2):226–31.

onix_3.0::thothThoth ONIX 3.0
onix_3.0::project_museProject MUSE ONIX 3.0
onix_3.0::oapenOAPEN ONIX 3.0
onix_3.0::jstorJSTOR ONIX 3.0
onix_3.0::google_booksGoogle Books ONIX 3.0
onix_3.0::overdriveOverDrive ONIX 3.0
onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
csv::thothThoth CSV
json::thothThoth JSON
kbart::oclcOCLC KBART
bibtex::thothThoth BibTeX
doideposit::crossrefCrossRef DOI deposit
onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
marc21record::thothThoth MARC 21 Record
marc21markup::thothThoth MARC 21 Markup
marc21xml::thothThoth MARC 21 XML

Share This Chapter!